Go Back To Menu
Close
- Mailing Form
-
Medical Report*
-
Go Back To Menu
Bladder cancer is the most common malignant tumor of the urinary system. Urothelial carcinoma accounts for about 90% of bladder cancers in the United States and Western Europe. In the Middle East and other regions, both urothelial and non-urothelial carcinomas exist, with the latter partly attributed to the prevalence of schistosomiasis in those areas.
Globally, the incidence of bladder cancer in men is 9.5/100,000 and the mortality rate is 3.3/100,000, about four times higher than in women. In 2020, approximately 500,000 new cases were diagnosed worldwide, with more than 210,000 deaths. Bladder cancer ranks as the sixth most common cancer in men and the ninth and nineteenth leading cause of cancer-related deaths among men and women, respectively.
Bladder cancer has a high incidence globally, particularly in Europe and North America, where industrial pollution and tobacco use are widespread. In contrast, some Asian countries, such as China, Japan, and regions of Southeast Asia, have relatively lower incidence rates but are seeing an increasing trend in recent years. Environmental and lifestyle factors play important roles in disease development.
1. Strong tumor invasiveness
Bladder cancer cells easily infiltrate the deep layers of the bladder wall, causing local tissue damage. If not controlled in time, the tumor may invade nearby organs, leading to severe complications.
2. High recurrence rate
Even after treatment, bladder cancer has a high recurrence rate, requiring patients to undergo long-term follow-up, which increases medical and psychological burden.
3. Impact on quality of life
Patients with bladder cancer often experience frequent urination, painful urination, and hematuria, which seriously affect normal life and work. In advanced stages, urinary retention and kidney function damage may occur.
Immune reconstruction cell therapy reinfuses functional immune cells to enhance the body’s anti-tumor immune response while restoring tumor-damaged immune function. In bladder cancer treatment, it can effectively identify and eliminate residual cancer cells, reduce postoperative recurrence rates, and is suitable for multiple recurrences, high-risk pathological types, and postoperative consolidation, thereby improving long-term outcomes and survival quality.
During traditional treatments such as surgery, radiotherapy, and chemotherapy, cancer patients often face immune dysfunction, increased infection risk, and slow recovery. To help patients better sustain treatment, improve tolerance, and enhance quality of life, scientifically designed phased immune reconstruction plans tailored to different treatment cycles are needed.
● Short-term plan: Rapidly enhance immunity through immune cell reinfusion to boost the effectiveness of anti-tumor treatment.
● Mid-term plan: Reduce side effects of traditional treatments, promote physical recovery, and complete standardized treatment courses.
● Long-term plan: Improve overall immunity through immune cell reconstruction, gut immune reconstruction, elemental immune reconstruction, and immune nutrition reconstruction, thereby improving quality of life and prolonging survival.
1. Transurethral resection of bladder tumor (TURBT)
TURBT is the primary surgical method for treating non-muscle-invasive bladder cancer. The tumor is removed through a cystoscope, which is minimally invasive and safe, and postoperative intravesical chemotherapy can help prevent recurrence.
2. Radical cystectomy
For muscle-invasive bladder cancer or high-risk recurrence cases, radical cystectomy with urinary tract reconstruction is required. Although more invasive, it is decisive in controlling progressive tumors.
3. Chemotherapy and targeted therapy
For advanced or metastatic cases, systemic chemotherapy combined with targeted therapy is a common approach. Regimens such as gemcitabine combined with cisplatin can delay disease progression and improve survival time.
4. Radiotherapy and bladder-preserving strategies
Some patients may undergo bladder-preserving therapy with radiotherapy combined with chemotherapy, particularly those unable to tolerate surgery. Treatment effectiveness must be carefully evaluated under multidisciplinary guidance.
5. Emerging treatment technologies
With advancements in medical technology, new minimally invasive approaches such as NanoKnife, photodynamic therapy, and tumor-treating fields are gradually being introduced into clinical practice, offering more treatment options for advanced or special patient groups.
Due to its invasiveness and high recurrence rate, bladder cancer requires early diagnosis and active treatment. Experts at United Life International Medical Center emphasize that immune reconstruction cell therapy brings new hope to bladder cancer patients, and comprehensive management combining multiple treatment methods is key to improving outcomes.
